ClinicalTrials.gg
RecruitingNCT06712004BCAIS-IUpdated Jul 17, 2025

A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke

A Phase 2 interventional study of Bevifibatide citrate injection in Ischemic Stroke, Acute, Ischemic Stroke and Cerebral Infarction, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Zhujiang Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
513th of 566
40 · median 271
Started
2025
with 106 others
Phase 2
71 of 754
29 open now
Primary completion
2025-09
later than 62 of 399 live
Registered
516th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 513th largest by planned enrollment of the 566 interventional ones that give a count, is one of 107 that started in 2025, is one of 71 in phase 2, reaches primary completion later than 62 of the 399 other live ones, and was the 516th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.

Read the detailed description

Bevifibatide is a derivative similar to Eptifibatide, differing by only one amino acid: in the position where Eptifibatide contains high arginine, it is replaced by arginine to form Bevifibatide. Bevifibatide can specifically bind to the GPIIb/IIIa receptor, inhibiting platelet aggregation or adhesion. It also inhibits the integrin receptor αvβ3, thereby suppressing the growth of vascular smooth muscle and playing an important role in preventing arterial re-occlusion. Bevifibatide is a post-marketing product indicated for unstable angina, non-Q wave myocardial infarction, non-ST segment elevation myocardial infarction, and anti-thrombotic therapy during and around percutaneous coronary intervention. Its clinical formulation is an injectable solution for intravenous administration. When Bevifibatide is used in combination with clinical baseline medications, it has a synergistic effect on anti-platelet aggregation. Early oral administration of aspirin and clopidogrel can achieve a rapid synergistic effect on anti-platelet aggregation.

Currently, there are no clinical trials assessing the relationship between the dosage of Bevifibatide and its efficacy in treating acute ischemic stroke. We conduct a single-center, randomized, double-blind, dose-response controlled clinical trial to preliminarily evaluate and compare the effectiveness of conventional dosage and low maintenance dosage of Bevifibatide citrate injection in improving neurological outcomes at 90 days and the incidence of symptomatic intracranial hemorrhage in patients suffering from acute ischemic stroke without large or medium-sized vessel occlusion, thereby determining a relatively safe dosage while maintaining the effectiveness of the medication, and providing a dosage basis for conducting large-sample randomized controlled trials.

03

Conditions studied

  • Ischemic Stroke, Acute
  • Ischemic Stroke
  • Cerebral Infarction
  • Brain Diseases

Keywords

  • Bevifibatide citrate injection
  • Dose-response controlled
  • Acute Ischemic Stroke
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any of the following presentations of acute ischemic stroke (AIS): ① Within 24 hours of time last known well and ineligible for intravenous thrombolysis (IVT) or endovascular treatment (EVT). ② More than 24 hours and less than 96 hours after time last known well but within 24 hours of ischemic stroke progression [worsening of ≥ 2 points on the NIHSS]; and ineligible for IVT or EVT without ICH confirmed by CT scan or MRI. ③ Treated with IVT followed by early neurological deterioration (worse NIHSS by ≥ 4 points) within the first 24 hours after IVT without ICH confirmed by CT scan or MRI. ④ Treated with IVT followed by no neurological improvement (Neurological improvement is defined as decrease in the NIHSS score by ≥ 2 points) from baseline within 4 to 24 hours after IVT without ICH confirmed by CT scan or MRI.
  • NIHSS score ≥ 3 immediately prior to trial entry.
  • Without visible large or medium intracranial vessel occlusion on CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA). (Qualifying mechanisms are: 1. hypoperfusion caused by arterial stenosis; 2. the initial occluded large or medium artery spontaneously recanalized or recanalized with IVT before the vascular imaging performed; 3. multiple or single distal emboli from cardiac or other sources in arterial branches too small to visualized on CTA or MRA; 4. lacunar infarct due to small vessel occlusion).
  • Written obtained from patients or their legal representatives.

Exclusion criteria

Exclusion Criteria:

  • CT or MR evidence of intracranial haemorrhage.
  • Pre-morbid disability with a mRS score ≥ 2.
  • Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, less than 30%.
  • Planned treatment with dual antiplatelet therapy within 1week of the index stroke.
  • Any history of a primary or other intracerebral (parenchymal) haemorrhage (intraventricular, subarachnoid, subdural, epidural).
  • Any untreated or incompletely treated intracranial aneurysm, any intracranial vascular malformation or any intracranial tumour.
  • Currently pregnant or lactating, and those planned to conceive.
  • Subjects with positive urine HCG test results.
  • Known allergy to study medication or concomitant medications.
  • Gastrointestinal bleeding, urinary tract bleeding, or other major systemic haemorrhage within 30 days.
  • Any major surgery within 6 weeks of the index stroke.
  • History of heparin-induced thrombocytopenia.
  • Expected lifespan less than 3 months.
  • Pre-existing neurological or psychiatric disease that would confound the neurological functional outcome evaluations.
  • Any of the following laboratory tests: [International Normalized Ratio]>2.0, PT>1.3 times normal value, count\<100 × 109/L, \<10g/dl.
  • Systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg after aggressive treatment.
  • Severe renal insufficiency ( \< 30 ml/min or serum creatinine > 220 μmol/L [2.5 mg/dl]).
  • History of liver dysfunction (/ALT exceeding the by more than twice) or cirrhosis.
  • Arterial tortuosity and/or other arterial diseases that prevent the expected internal thrombectomy device from reaching the target vessel.
  • Unlikely to be available for 90-day follow-up.
  • Current participation in another treatment clinical trial.
  • Other conditions that are not suitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Routine maintenance dose group

    Undergoing bevifibatide citrate injection with intravenous bolus of 220μg/kg (0.11ml/kg) over 1 to 2 minutes, followed by continuous intravenous bolus at a rate of 2.5μg/kg/min (0.075ml/kg/h) for 24 hours.

    Drug: Bevifibatide citrate injection

  • Experimental
    Low maintenance dose group

    Undergoing bevifibatide citrate injection with intravenous bolus of 220μg/kg (0.11ml/kg) over 1 to 2 minutes, followed by continuous intravenous bolus at a rate of 2.0μg/kg/min (0.06ml/kg/h) for 24 hours.

    Drug: Bevifibatide citrate injection

Interventions

  • DrugBevifibatide citrate injection

    Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.

    Also known as: BETAGRIN

06

What researchers measure

Primary outcomes

  1. The modified Rankin Scale (mRS) score

    The mRS scores are evaluated by experienced researchers trained in standard neurological function assessments using information obtained from patients or their families.

    Time frame: 90(±7) days

  2. Symptomatic intracranial hemorrhage (sICH)

    ICH will be evaluated according to the Heidelberg Bleeding Classification. sICH is diagnosed if the new observed ICH is associated with any of the following conditions: 1) NIHSS score increased more than 4 points than that immediately before worsening; 2) NIHSS score increased more than 2 points in one category; 3) Deterioration led to intubation, hemicraniectomy, external ventricular drain placement or any other major interventions. Additionally, the symptom deteriorations could not be explained by causes other than the observed ICH.

    Time frame: Within 48 hours

Secondary outcomes

  1. mRS score 0-1 at 30 days

    Proportion of patients without disability at 30 days.

    Time frame: 30(±3) days

  2. mRS score 0-2 at 30 days

    Proportion of patients with functional independence at 30 days.

    Time frame: 30(±3) days

  3. mRS score 0-1 at 90 days

    Proportion of patients without disability at 90 days.

    Time frame: 90(±7) days

  4. mRS score 0-2 at 90 days

    Proportion of patients with functional independence at 90 days.

    Time frame: 90(±7) days

  5. Change of the National Institute of Health Stroke Scale (NIHSS) score from baseline to 72 hours

    Change of the NIHSS score from baseline to 72 hours

    Time frame: 72(±12) hours

  6. Change of the NIHSS score from baseline to 6 days

    Change of the NIHSS score from baseline to 6 days

    Time frame: 6(±1) days

  7. Change of the NIHSS score from baseline to 90 days

    Change of the NIHSS score from baseline to 90 days

    Time frame: 90(±7) days

  8. Health-related quality of life

    Health-related quality of life is assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L)

    Time frame: 90(±7) days

  9. Any ICH

    ICH will be evaluated according to the Heidelberg Bleeding Classification.

    Time frame: Within 48 hours

  10. Mortality

    Mortality rates are defined as the number of deaths observed divided by the number of subjects observed over the 90-day study period.

    Time frame: 90(±7) days

  11. Incidence of serious adverse events

    Including both bleeding and non-bleeding adverse events. Among these, bleeding adverse events encompass: purpura, minor oral and nasal mucosal bleeding, ecchymosis, gingival bleeding, epistaxis, minor gastrointestinal or urinary tract bleeding, hematomas from spontaneous or minor trauma, hemarthrosis, intracranial hemorrhage, and bleeding that poses hemodynamic compromise or requires intervention. Serious adverse events are defined as undesirable medical events that occur after a subject has received the investigational product, including death, life-threatening conditions, permanent or significant disability, or loss of function, hospitalization or prolongation of hospital stay due to the event, and congenital anomalies or birth defects.

    Time frame: 90(±7) days

  12. Incidence of adverse events

    Including both bleeding and non-bleeding adverse events. Among these, bleeding adverse events encompass: purpura, minor oral and nasal mucosal bleeding, ecchymosis, gingival bleeding, epistaxis, minor gastrointestinal or urinary tract bleeding, hematomas from spontaneous or minor trauma, hemarthrosis, intracranial hemorrhage, and bleeding that poses hemodynamic compromise or requires intervention. Adverse events are defined as any harmful or unintended responses occurring in a clinical trial that may be related to the investigational product. There should be at least a reasonable possibility of a causal relationship between the study product and the adverse reaction, meaning that a connection cannot be ruled out.

    Time frame: 90(±7) days

  13. Inhibitory rate of platelet aggregation at 4 hours

    ADP-induced platelet aggregation.

    Time frame: 4 hours

  14. Inhibitory rate of platelet aggregation at 24 hours

    ADP-induced platelet aggregation.

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2025, 6 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 6 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 2, 2024
StartActual
Feb 10, 2025
Primary completionEst.
Sep 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712004
Lead sponsor
Zhujiang Hospital
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Feb 10, 2025
Primary completion
Sep 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jul 17, 2025

Study contacts

Chuanzhi Duan, MD
Contact
doctor_duanzj@163.com
02062782757
Xin Feng, MD
Contact
13681134001@163.com
13681134001
Chuanzhi Duan, MD
study director · Southern Medical University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion